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A B S T R A C T
Introduction: Our aim was to describe how the prevalence of subjects exposed to environmental tobacco smoke
(ETS) has changed from 1992 to 2012 in Finland. We also investigated the association between ETS and chronic
bronchitis and cause-specific and all-cause mortality.
Methods: The study population is composed of 38 494 subjects aged 25–74 years who participated in the
National FINRISK Study between 1992 and 2012. Each survey included a standardized questionnaire on ex-
posure to ETS, symptoms of chronic bronchitis, smoking habits and other risk factors, and clinical measurements
at the study site. Data on mortality was obtained from the National Causes of Death Register.
Results: In 2012, 5% of the participants were exposed to ETS compared to 25% in 1992. The adjusted odds ratio
(OR) for ETS exposure in 2012 compared with that in 1992 was 0.27, p < 0.001. Exposure to ETS was more
common in men than in women and among smokers than in non-smokers. Exposure to ETS was in turn asso-
ciated with chronic bronchitis, OR 1.63 (95% confidence interval 1.49–1.78), – also separately both at work (OR
1.36) and at home (OR 1.69). Subjects with exposure to ETS had significantly increased all-cause (hazard
ratio=HR 1.15, 1.05–1.26) and cardiovascular mortality (HR 1.26, 1.07–1.47). However, when stratified by
smoking ETS was associated with all-cause mortality only in smokers (HR 1.31, 1.15–1.48).
Conclusion: The proportion of subjects exposed to ETS decreased substantially during the study. Additionally,
ETS exposure was associated with chronic bronchitis throughout the study and increased all-cause and cardi-
ovascular mortality.
1. Introduction
Environmental tobacco smoke (ETS) originates from tobacco com-
bustion [1]. ETS is a major indoor air pollutant when there is smoking
inside [1,2]. Furthermore, indoor air pollution matters because people
can spend up to 90% of their time indoors [2]. Inhalation of tobacco
smoke causes airway inflammation and enlargement of the mucous
glands, leading to increased phlegm production [3] and chronic bron-
chitis [4]. The main risk factor for chronic bronchitis is active smoking
[4], but exposure to occupational airborne particles, biomass burning,
chest infections in childhood and ETS also play a role in its pathogenesis
[5–9].
In the FINRISK Study in Finland, smoking has decreased in men
during 1982 and 2007 [5]. In another study in nine European countries
(including also Finnish cohorts) [10], smoking has declined between
1985 and 2000 among men from all educational levels and among the
tertiary and higher secondary educated women. Smoking rates have
also decreased in the US population [11]. Parallel to the decrease in
smoking, during recent decades in Finland, the prevalence of chronic
bronchitis declined from 19% to 13% and 13% to 11%, respectively, in
men and women [5]. In Sweden, particularly symptoms of bronchitis
decreased in conjunction with a 30% decrease in the prevalence of
smoking [12]. Chronic bronchitis can in turn lead to the development of
COPD (chronic obstructive pulmonary disease) [13]. With decreasing
smoking, the prevalence of COPD has also decreased or been stable
during the same time period [14–16]. The decrease in smoking
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prevalence has also led to a reduction in ETS [5,12]. In altogether 26
European centers, the prevalence of individuals exposed to ETS de-
creased from 38.7% in 1990–1994 to 7.1% in 2008–2011 [17].
ETS exposure has also been associated with increased mortality
[18]. In never-smoking women, ETS exposure at home has been asso-
ciated with increased all-cause mortality (hazard ratio= [HR] 1.15)
and cardiovascular mortality (HR 1.37), and ETS exposure at work has
been associated with increased cancer mortality (HR 1.19)18. The pre-
sent study describes how the prevalence of subjects exposed to ETS has
changed from 1992 to 2012. We also examined the association between
ETS and chronic bronchitis and cause-specific and all-cause mortality
stratified by smoking.
2. Methods
2.1. Sample
The study population consists of 38 494 subjects aged 25–74 years
who participated in five cross-sectional surveys of the National FINRISK
Study between 1992 and 2012 carried out by the National Institute for
Health and Welfare (Table 1). At each survey [5,19], an independent
random population sample was taken from the population register in six
geographical areas: the provinces of North Karelia and Kuopio in
eastern Finland since 1972, the Turku-Loimaa area in south-western
Finland since 1982, the capital area (the cities of Helsinki and Vantaa)
since 1992 and the provinces of Oulu (since 1997) and Lapland (since
2002) in northern Finland. The sampling and study methods complied
with the protocol of the World Health Organisation MONICA (Multi-
national MONItoring of trends and determinants in CArdiovascular
disease) project [20] and since 2002, the later recommendations of the
European Health Risk Monitoring Project (EHRM) [21].
2.2. Questionnaire
At each examination, the participants received a self-administered
questionnaire [5]. Exposure to environmental tobacco smoke (ETS) was
determined by the question ‘How many hours do you daily spend in
indoor spaces where you have to inhale other people's smoke?’ Since
2002 onwards exposure to ETS separately at work, at home and at other
places was enquired. The diagnosis of chronic bronchitis was based on a
positive response to the same standard question ‘Do you bring up
phlegm on most days or nights for at least three months each year’
[5,13,22] in the questionnaire. Smoking, education, occupation, mar-
ital status, a history of hypertension during the preceding 12 months, a
history of diagnosed myocardial infarction and self-reported asthma
were asked with standardized questions in the questionnaire. Body
mass index (BMI) (kg/m2) was calculated from height and weight
measured at the examination.
2.3. Definitions
For the present study, exposure to ETS was first classified as a binary
variable (no/yes). Between 2002 and 2012, exposure to ETS was ad-
ditionally classified into five categories: no exposure, exposure only at
work, only at home, only at other places and multiple exposure (if a
subject had exposure to ETS e.g. both at work and at home). Smoking
status was classified into the three categories: never-, ex- and current
smokers (Table 1). Smokers had smoked regularly at least one year. Ex-
smokers had stopped smoking at least one month before the survey.
Excluded from analyses (altogether n=515) were those who had no
complete data on smoking and those smokers who had quit smoking
less than a month ago (thus could not be classified into ex-smokers
because of their short period of abstinence) [5].
The level of education was classified into four categories: elemen-
tary school, vocational school, upper secondary school or college and
an academic degree. Occupation was graded into seven categories:
agriculture and dairy farming; factory, mine and construction work;
office work; unemployed; students; housewives and pensioners. Marital
status was broken down into four categories: married or cohabitation
without marriage, unmarried, divorced and widowed. The area of re-
sidence was categorized into four classes: North Karelia and Kuopio, the
Turku-Loimaa area, Lapland and Oulu, and the capital area.
2.4. Assessment of mortality
Data on mortality was obtained from the National Causes of Death
Register. Between 1992 and 2012 two different revisions of the
International Classification of Diseases (ICD) were used in Finland –the
ICD-9 between 1987 and 1995 and the ICD-10 since 1996. In the pre-
sent study, a concordance table was used for bridging the two revisions
of ICD [23], and the underlying causes of death were classified into the
following four major categories: respiratory causes, cardiovascular
diseases, cancer and other causes. The listing of the corresponding ICD-
9 and ICD-10 codes has been shown earlier [24].
Table 1
Description of the study population by the year of examination.
n The year of examination
1992 1997 2002 2007 2012
Invited 7927 11 500 13 498 12 000 10 000
Examined (men/women) 2849/3202 4253/4193 4482/5098 3740/4253 3041/3383
Non-responders (men/women) 1116/760 1747/1307 2267/1651 2260/1747 1959/1617
Smoking status
never smokers 2596 3752 4294 3634 3034
ex-smokers 1622 2317 2490 2425 1962
current smokers 1811 2117 2725 1855 1345
excluded* 22 260 71 79 83
Chronic bronchitis† 855 1085 1175 879 686
Exposure to environmental tobacco smoke (= ETS)‡ (%) 25.0 12.6 11.6 10.1 5.0
Mean hours/day (SD)§in exposed 4.98 (5.32) 4.63 (5.45) 5.13 (5.70) 3.93 (5.13) 7.11 (8.03)
Exposure to ETS at work/at home/other‡ (%) – – 5.4/3.4/4.2 4.0/2.2/5.0 2.3/2.1/1.9
*Excluded were subjects without data on smoking or when last smoked and ex-smokers who had quit smoking less than one month ago.
†In subjects having data of smoking.
‡ Self-reported exposure to environmental smoke at each examination in subjects having data of smoking habits.
§In subjects exposed to ETS and having data on smoking habits. SD= standard deviation.
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2.5. Statistical methods
Logistic regression analysis was used to study age-specific pre-
valence odds ratios (ORs) for exposure to ETS (n= 36 594) during 1992
and 2012. Two models were fitted. The first model included the fol-
lowing variables: the survey year (as a continuous variable), smoking
status and the age –group (as categorical variables); the second model
additionally included the following categorical variables: sex, occupa-
tion, education and the area of residence. The results are presented as
odds ratios with 95% confidence intervals (95% CI). A significance level
of p < 0.05 was used.
Multivariable logistic regression analysis was used to examine the
association between exposure to ETS and chronic bronchitis
(n= 34 101). Those who had no data on the symptoms of chronic
bronchitis or on self-reported asthma and subjects who reported having
asthma diagnosed by a doctor were excluded. A separate multivariable
logistic regression analysis was done from 2002 onwards to study the
relationship of ETS exposure at work, at home and at other places to
chronic bronchitis (n= 20 932). In smokers, additional adjustment for
pack-years was done as a continuous variable (pack-years= years of
smoking x the daily number of cigarettes smoked/20).
ANCOVA analysis was used to compare mean hours of ETS exposure
by smoking status and at work, home and other places. These analyses
were adjusted for sex, the age group, the survey year, smoking status
and the area of residence.
Cox proportional hazards regression models were used to analyse
the relation between ETS exposure and all-cause and cause-specific
mortality. Among subjects with variables needed for multivariate ana-
lyses 506 subjects had participated in the FINRISK study twice between
1992 and 2012. Among these subjects, the values of the first survey
were used in the mortality analyses. The mortality analyses
(n=33 266) were first adjusted for the age group and smoking status
and then additionally adjusted for sex, education, marital status, the
area of residence, a history of myocardial infarction and the presence of
hypertension as categorical variables, and the survey year and body
mass index as continuous variables. In smokers, the mortality analysis
was additionally adjusted for pack-years. The results are presented as
hazard ratios with 95% confidence intervals. A significance level of
p < 0.05 was used.
Statistical analyses were performed with SPSS 22 for Windows. All
surveys had ethics approval from the ethics committees operating at the
time of data collection in 2001 and by the ethics committee at the
National Institute for Health and Welfare in Helsinki, and participants
have given their informed consent.
3. Results
Between 1992 and 2012 the percentage of subjects who were ex-
posed to ETS decreased from 25% to 5% (Table 1). Between 2002 and
2012 the percentage of subjects who were exposed to ETS at work, at
home and at other places also decreased (Table 1). However, in subjects
exposed to ETS, the mean hours spent daily in ETS exposure were
highest in 2012 (Table 1).
In logistic regression (Table 2), there was a significant (p < 0.001)
decreasing trend in exposure to ETS between 1992 and 2012 (OR
0.933). After inclusion other covariates into the Model 2, the ORs de-
creased only slightly. In Model 2, the adjusted OR for exposure to ETS
in 2012 compared to that in 1992 was 0.27 (=0.93620). There was also
an interaction (p < 0.001) between the age group and the decreasing
yearly trend, so that the decreasing trend was insignificant in the oldest
age group (Table 2). Generally, exposure to ETS was significantly more
common in men than in women (OR 1.76 (95% CI 1.64–1.89)) and in
smokers than in never smokers (OR 2.29 (95% CI 2.12–2.48)) (not
shown).
ETS exposure was in turn associated with chronic bronchitis (OR
1.63) (Table 3). Stratified by smoking (Table 3), ETS exposure was
associated with chronic bronchitis in smokers (OR 1.75 (95% CI
1.55–1.97)). ETS exposure was related to chronic bronchitis in ex-
smokers and never smokers too (OR 1.47 (95% CI 1.20–1.81) and 1.48
(95% CI 1.24–1.76), respectively) although ETS exposure was less
pronounced (p < 0.001) in ex-smokers and never smokers than in
smokers (Table 3). In smokers, exposure to ETS was still significantly
associated with chronic bronchitis after additional adjusting for pack-
years (OR 1.53 (95% CI 1.35–1.73)) (not shown). Generally, there were
no significant interactions between ETS exposure and the survey year,
sex, the age group or occupation on the presence of chronic bronchitis.
ETS exposure separately at work, at home and at other places was
significantly associated with chronic bronchitis (Table 4), and the mean
daily hours spent in ETS exposure were significantly higher at home
than at work. Stratified by the smoking group (not shown), ETS ex-
posure at work and at other places was significantly associated with
chronic bronchitis in smokers (OR 1.51 (95% CI 1.14–2.02) and 1.58
(95% CI 1.19–2.10), respectively). ETS exposure at home was sig-
nificantly associated with chronic bronchitis both in smokers and never
smokers (OR 1.68 (95% CI 1.26–2.24) and 2.03 (95% CI 1.20–3.42),
respectively). In smokers, after additional adjusting for the pack-years
ETS exposure at work was still associated with chronic bronchitis with
OR 1.39 (95% CI 1.02–1.87).
ETS exposure was associated with increased mortality (Table 5). In
Model 1, after adjusting for the age group and smoking status HRs
(=hazard ratios) for all-cause and cardiovascular mortality were 1.25
and 1.37, respectively, and the HRs decreased after a multivariable
adjustment in Model 2. When the analysis was performed separately in
each smoking group (Table 5) ETS exposure was associated with in-
creased mortality only among smokers. In smokers, after additional
adjusting for pack-years HRs for all-cause mortality were 1.18
(1.04–1.35, p=0.011) and 1.14 (1.00–1.30, p= 0.058) in Model 1 and
2, respectively. After including chronic bronchitis into the Model 2,
there was an interaction between ETS and chronic bronchitis on mor-
tality in men (p=0.035) so that HRs for all-cause mortality in men
with chronic bronchitis without and with ETS exposure were 1.25
(1.11–1.41) and 1.55 (1.29–1.85), respectively, compared with men
without chronic bronchitis or ETS exposure.
Fig. 1 illustrates the effect of ETS exposure on survival during the
study. In Fig. 1 (adjusted for the age group and smoking status, Model
1), the HRs for all-cause mortality were 1.13 (0.99–1.29, p= 0.063)
and 1.36 (1.21–1.52, p < 0.001), respectively, in subjects with ex-
posure to ETS<2 h/day and ≥2 h/day. In Model 2 (not shown in
Fig. 1), the corresponding HRs were 1.00 (0.88–1.14, p= 0.980) and
1.29 (1.15–1.46, p < 0.001), respectively.
4. Discussion
In the present study, the proportion of subjects exposed to ETS de-
creased clearly during the last decades. ETS exposure was significantly
associated with chronic bronchitis in all smoking groups. ETS exposure
was also associated with increased all-cause and cardiovascular mor-
tality. But when mortality analysis was stratified by smoking status
there was an increased risk for all-cause mortality only in smokers.
In the present study, the prevalence of subjects exposed to ETS in
2012 was 5%, which is consistent with another European study [17].
With the reduction in smoking prevalence and policies to restrict
smoking in public places ETS exposure has been decreasing both in
Europe and in the United States [17,25]. In Finland, the first law to
restrict smoking was put into operation in 1977 [26], and since the
1980s’ ETS exposure has decreased significantly [5]. The influence of
enforcements of the tobacco laws restricting smoking at worksites in
1995 and banning of smoking in bars and restaurants in 2007 [27] can
be seen also in this study as clear decreases in exposure to ETS between
1992 and 1995 and between 2007 and 2012. Between 1985 and 2000
in Finland, ETS exposure at work has been three times more common in
smokers than in non-smokers, but ETS exposure has decreased both
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among never smokers and smokers [28]. In the present study, ETS ex-
posure was still more frequent in smokers than in never smokers and in
men than in women.
In the present study, exposure to ETS was associated with chronic
bronchitis, also separately both at work and at home. Among non-
smokers, chronic bronchitis has been associated with the number of
smokers at work [29]. Living with smokers before the age of 18 has
associated with chronic phlegm production in adulthood [8]. In female
never smokers, ETS exposure at work has a stronger association with
COPD than ETS exposure at home [7]. In another study, the risk of
developing COPD has been 1.60 and 1.68 times higher in the highest
quartile of ETS exposure in the workplace and at home, respectively,
after controlling for smoking history and other factors [30].
It has been proposed, that exposure to the particle phase rather than
the vapour phase of exhaled cigarette smoke is associated with chronic
bronchitis in passive smoking [9]. It is not known how low levels of ETS
adversely effects the airways. Additionally, ETS can be also derived
from e-cigarettes, though at lower levels than from conventional ci-
garettes [31]. In the present study, according to the odds ratios ETS
exposure was more strongly associated with chronic bronchitis in
smokers than in never and ex-smokers, but smokers had the highest
mean daily ETS exposure. In Switzerland, an increasing risk for chronic
bronchitis with increasing daily hours of ETS exposure has also been
found [9].
The risk of chronic bronchitis has doubled if there has also been
occupational exposure to biological dusts [6]. However, in one study,
there was no evidence that occupational exposure to gas and dusts
modified the association between ETS and COPD [30]. In the present
study, there was no significant interaction between ETS and occupation
on chronic bronchitis. Our classification of occupations into the seven
categories gave only a rough estimate of occupational exposures,
however, and the classification was done only once at each survey.
According to our earlier results, male smoking and the prevalence of
chronic bronchitis in Finland has been decreasing [5], which is in line
with the present results of decreasing ETS exposure. In the present
Table 2
Adjusted odds ratios (OR) for the trend in exposure to environmental tobacco smoke (ETS) during 1992–2012 by age group.
n Model 1* Model 2† p-value
OR‡ (95% CI) for 1992–2012 p-value OR‡ (95% CI) for 1992–2012
Age group
25–34 7043 0.931 (0.921–0.942) <0.001 0.938 (0.927–0.949) <0.001
35–44 7760 0.918 (0.908–0.928) <0.001 0.921 (0.911–0.932) <0.001
45–54 8190 0.924 (0.915–0.934) <0.001 0.925 (0.915–0.936) <0.001
55–65 8581 0.951 (0.941–0.962) <0.001 0.950 (0.939–0.962) <0.001
65–74 5020 0.986 (0.964–1.009) 0.230 0.998 (0.974–1.023) 0.871
All 36 594 0.933 (0.928–0.938) <0.001 0.936 (0.931–0.942) <0.001
*From a logistic regression model adjusted for smoking status and age-group. 95% CI=95% confidence interval.
†From a logistic regression model adjusted for smoking status, age-group, gender, occupation, education and area of residence.
‡OR is presenting the yearly change in exposure to environmental tobacco smoke.
Table 3
Multivariable adjusted odds ratios (OR) for chronic bronchitis during
1992–2012 by exposure to environmental tobacco smoke (ETS).
Exposure to ETS n mean hours of
ETS/day (SD*)
OR (95% CI†) for chronic
bronchitis
All‡ (n= 34 101) p-value
Exposed to ETS 4432 4.84 (5.58) 1.63 (1.49–1.78) < 0.001
Exposure to ETS, mean hours/day
0< & < 2 2368 1.25 (0.45) 1.52 (1.36–1.71) < 0.001
≥2 2064 8.96 (5.90) 1.74 (1.55–1.95) < 0.001
Smoking group§
Never-smokers (n= 15 454)
Exposed to ETS 1329 4.12 (5.05) 1.48 (1.24–1.76) < 0.001
Ex-smokers
(n= 9713)
Exposed to ETS 1003 3.84 (4.56) 1.47 (1.20–1.81) < 0.001
Smokers (n= 8934)
Exposed to ETS 2100 5.78 (6.16) 1.75 (1.55–1.97) < 0.001
*Standard deviation.
†95% CI= 95% confidence interval.
‡From a logistic regression model adjusted for gender, survey year, age group,
smoking status, occupation, education and area of residence. Subjects without
ETS exposure as a reference group.
§From a logistic regression model adjusted for gender, survey year, age group,
occupation, education and area of residence. For each smoking category sepa-
rately. Subjects without ETS exposure as a reference group.
Table 4
Multivariable adjusted odds ratios (OR) for chronic bronchitis during 2002–2012 by environmental tobacco smoke (ETS) at work, at home and other places.
Exposure to ETS n mean hours of ETS/day (SD*) p-value† OR (95% CI*) for chronic bronchitis (exam 2002/2007/2012) p-value‡
No exposure to ETS 18 926 – 1 ref
At work (only) 726 3.87 (3.58) ref 1.36 (1.10–1.69) 0.005
At home (only) 405 8.66 (7.51) <0.001 1.69 (1.34–2.14) <0.001
At other places (only) 642 1.75 (1.82) <0.001 1.56 (1.27–1.92) <0.001
Combination (e.g. at work + at home) 233 10.24 (8.27) <0.001 2.60 (1.94–3.50) <0.001
*SD= standard deviation. 95% CI=95% confidence interval.
†From ANCOVA analysis adjusted for gender, survey year, age group, smoking status and area of residence.
‡From a logistic regression model adjusted for gender, survey year, age group, smoking status, occupation, education and area of residence.
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study, there was no significant interaction between ETS and the survey
year on chronic bronchitis. Thus, ETS exposure was similarly associated
with chronic bronchitis throughout the study.
In the present study, the clear association between ETS exposure
and mortality among smokers may indicate that perhaps simultaneous
active and passive smoking can have detrimental additive effects on
health. In the present study, chronic bronchitis strengthened the effect
of ETS on mortality in men. Additionally, in subjects with ETS exposure
≥2 h/day the association between ETS and mortality was stronger.
Worldwide approximately 1.0% of all deaths among non-smokers have
been estimated to be caused by environmental tobacco smoke [32]. ETS
exposure in non-smokers has also increased mortality from lung cancer
and COPD [33,34]. Additionally, ETS has been associated with a greater
burden of cardiovascular risk factors [35], such as higher BMI and
fasting glucose [36], and with endothelial dysfunction and increased
plasma fibrinogen levels [37].
The strength of our study was a large study population and a long
follow-up. The participation rates decreased during the follow-up,
probably leaving out more of those with higher morbidity than heal-
thier persons [5]. According to an earlier questionnaire study, however,
non-responders evaluated by a telephone interview have not reported
more respiratory symptoms than responders [38]. In addition, probably
the response rates did not differ by ETS exposure. Earlier, a high
validity of self-reported exposure to ETS [39] has been found, though a
change in the exposure pattern may have happened during the course of
the present study.
In mortality analyses, there was only the baseline measurement of
smoking and the other variables. We know that a large proportion of
smokers have stopped smoking during the follow up [19]. However,
misclassification of smokers and ex-smokers would only weaken the
observed association between ETS and mortality. Unfortunately, pul-
monary functions were not measured, and thus we could not study the
association between ETS and COPD. There was also no biological
marker for exposure to smoke like measurements of cotinine in the
blood [40].
In conclusion, exposure to ETS has decreased during the study
period. The decrease in ETS may be a result of decreasing smoking
prevalence and restrictions of smoking in public places. In the present
study, exposure to ETS was associated with an increased risk for chronic
bronchitis and elevated cardiovascular and all-cause mortality.
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Table 5
Adjusted hazards ratios* (HR) for all-cause and cause-specific mortality during 1992–2015 by exposure to environmental tobacco smoke (ETS).
Cause of death No exposure to ETS Exposure to ETS Model 1* Model 2†
n of deaths/n in analysis
All-causes
All 2907/28 954 594/4312 1.25 (1.14–1.37) <0.001 1.15 (1.05–1.26) 0.004
Never-smokers 1113/13 859 109/1293 1.04 (0.85–1.27) 0.711 0.94 (0.77–1.15) 0.523
Ex-smokers 964/8561 106/975 1.12 (0.91–1.37) 0.298 1.03 (0.83–1.26) 0.806
Smokers 830/6534 379/2044 1.42 (1.25–1.60) <0.001 1.31 (1.15–1.48) <0.001
Cause-specific causes n in analysis= 28 954 n in analysis = 4312
Respiratory diseases 125 31 1.37 (0.91–2.07) 0.131 1.29 (0.85–1.95) 0.235
Cardiovascular disease 1007 206 1.37 (1.17–1.60) <0.001 1.26 (1.07–1.47) 0.005
Cancer 862 151 1.04 (0.87–1.24) 0.675 0.99 (0.82–1.18) 0.893
Other 913 206 1.31 (1.12–1.53) 0.001 1.19 (1.01–1.40) 0.034
*from Cox proportional hazards regression model. Adjusted for age group and smoking status. Subjects without exposure to ETS as a reference group. In cause-specific
mortality for each cause separately. 95% CI=95% confidence interval. †from Cox proportional hazards regression model. Adjusted for age group, smoking status,
gender, survey year, education, marital status, body mass index, history of myocardial infarction, presence of hypertension and the area of residence. Subjects
without exposure to ETS as a reference group. In cause-specific mortality for each cause separately.
Fig. 1. Cumulative survival probability
curves by exposure to environmental to-
bacco smoke (ETS) based on Cox's propor-
tional hazards regression model, adjusted
for age group and smoking status. No ETS as
a reference group. N of deaths (n in analysis)
2907 (28 954), 254 (2289) and 340 (2023),
respectively, among subjects with no ETS,
with ETS 0<&<2 h/day and with
ETS≥ 2 h/day. The HRs (=hazard ratios)
for all-cause mortality were 1.13
(0.99–1.29) and 1.36 (1.21–1.52), respec-
tively, among subjects with ETS 0<&
<2 h/day and with ETS≥ 2 h/day com-
pared with subjects with no ETS.
M.K. Pelkonen, et al. Respiratory Medicine 154 (2019) 34–39
38
our names in this paper and thus sign consent to publication.
References
[1] M.S. Jaakkola, Environmental tobacco smoke and respiratory diseases, Eur. Respir.
Monogr. 15 (2000) 322–383.
[2] M. Hulin, M. Simoni, G. Viegi, I. Annesi-Maesano, Respiratory health and indoor air
pollutants based on quantive exposure assessments, Eur. Respir. J. 40 (2012)
1033–1045.
[3] J.C. Hogg, F. Chu, S. Utokaparch, et al., The nature of small-airway obstruction in
chronic obstructive pulmonary disease, N. Engl. J. Med. 350 (2004) 2645–2653.
[4] J.M. Sethi, C.L. Rochester, Smoking and chronic obstructive pulmonary disease,
Clin. Chest Med. 21 (2000) 67–86.
[5] M.K. Pelkonen, I.-L. Notkola, T.K. Laatikainen, H.O. Koskela, Twenty-five year
trends in prevalence of chronic bronchitis and the trends in relation to smoking,
Respir. Med. 108 (2014) 1633–1640.
[6] K. Radon, K. Büsching, J. Heinrich, et al., Passive smoking exposure. A risk factor
for chronic bronchitis and asthma in adults? Chest 122 (2002) 1086–1090.
[7] M. Simoni, S. Baldacci, R. Puntoni, et al., Respiratory symptoms/diseases and en-
vironmental tobacco smoke (ETS) in never smoker Italian women, Respir. Med. 101
(2007) 531–538.
[8] G.L. David, W.-P. Koh, H.-P. Lee, M.C. Yu, S.L. London, Childhood exposure to
environmental tobacco smoke and chronic respiratory symptoms in non-smoking
adults: the Singapore Chinese Health Study, Thorax 60 (2005) 1052–1058.
[9] P. Leuenberger, J. Schwartz, U. Ackermann-Liebrich, et al., Passive smoking ex-
posure in adults and chronic respiratory symptoms (SAPALDIA Study), Am. J.
Respir. Crit. Care Med. 150 (1994) 1222–1228.
[10] K. Giskes, A.E. Kunst, J. Benach, et al., Trends in smoking behaviour between 1985
and 2000 in nine European countries by education, J. Epidemiol. Community
Health 59 (2005) 395–401.
[11] C. Halldin, B.C. Doney, E. Hnizdo, Changes in prevalence of chronic obstructive
pulmonary disease and asthma in the US population and associated risk factors,
Chronic Respir. Dis. 12 (2015) 47–60.
[12] H. Backman, L. Hedman, S.-V. Jansson, A. Lindberg, B. Lundbäck, E. Rönmark,
Prevalence in respiratory symptoms and asthma in relation to smoking – two cross-
sectional studies ten years apart among adults in northern Sweden, World Allergy
Organ. J 7 (2014) 1-4551-7-1.
[13] M. Pelkonen, I.-L. Notkola, A. Nissinen, H. Tukiainen, H. Koskela, Thirty-year cu-
mulative incidence of chronic bronchitis and COPD in relation to 30-year pul-
monary function and 40-year mortality. A follow-up in middle-aged rural men,
Chest 130 (2006) 1129–1137.
[14] H. Backman, B. Eriksson, E. Rönmark, et al., Decreased prevalence of moderate to
severe COPD over 15 years in northern Sweden, Respir, Med 114 (2016) 103–110.
[15] L. Bhatta, L. Leivseth, X.-M. Mai, et al., Prevalence and trend of COPD from 1995-
1997, Respir. Med. 138 (2018) 50–56.
[16] T.M. Vasankari, O. Impivaara, M. Heliövaara, No increase in the prevalence of
COPD in two decades, Eur. Respir. J. 36 (2010) 766–773.
[17] C. Flexeder, J.-P. Zock, D. Jarvis, et al., Second-hand smoke exposure in adulthood
and lower respiratory health during 20 year follow up in the European Community
Respiratory health Survey, Respir. Res. 20 (2019) 33, https://doi.org/10.1186/
s12931-019-0996-z.
[18] W. Wen, X.O. Shu, Y.-T. Gao, et al., Environmental tobacco smoke and mortality in
Chinese women who have never smoked: prospective cohort study, BMJ (2006),
https://doi.org/10.1136/bmj.38834.522894.2F.
[19] E. Vartiainen, T. Laatikainen, M. Peltonen M, et al., Thirty-five-year trends in car-
diovascular risk factors in Finland, Int. J. Epidemiol. 39 (2010) 504–518.
[20] WHO MONICA project Principal Investigators, the World Health Organization
MONICA Project (monitoring trends and determinants of cardiovascular disease): a
major international collaboration, J. Clin. Epidemiol. 41 (1988) 105–114.
[21] H. Tolonen, K. Kuulasmaa, T. Laatikainen, H. Wolf, the European Health Risk
Monitoring Project, Recommendation for Indicators, International Collaboration,
Protocol and Manual of Operations for Chronic Disease Risk Factor Surveys,
(October 2002) www-publications from EHRM Project. URL http://www.ktl.fi/
ehrm.
[22] G.A. Rose, H.B. Blackburn, Cardiovascular Survey Methods, Monograph Series,
World Health Organization, Geneva, 1968, pp. 177–178.
[23] F. Janssen F, A.E. Kunst, ICD coding changes and discontinuities in trends in cause
-specific mortality in six European countries, 1950-99, Bull. World Health Organ. 82
(12) (2004) 904–913.
[24] M.K. Pelkonen, I.-L. Notkola, T.K. Laatikainen, P. Jousilahti, Chronic bronchitis in
relation to hospitalization and mortality over three decades, Respir. Med. 123
(2017) 87–93.
[25] S.E. Perlman, c. Chermov, S.M. Farley, et al., Exposure to secondhand smoke among
nonsmokers in New York City in the context of recent tobacco control policies:
current status, changes over the past decade, and national comparisons, Nicotine
Tob. Res. 18 (2016) 2065–2074.
[26] A. Helome, S. Helakorpi, J. Honkonen, P. Danielsson, A. Uutela, Exposure to sec-
ondhand smoke in Finnish workplaces and compliance with national smoke-free
workplace legislation, Scand. J. Publ. Health 39 (2011) 723–729.
[27] J. Reijula, K. Reijula, The impact of Finnish tobacco legislation on restaurant
workers' exposure to tobacco smoke at work, Scand. J. Publ. Health 38 (2010)
724–730.
[28] P. Jousilahti, S. Helakorpi, Prevalence of exposure to environmental tobacco smoke
at work and at home – 15 –year trends in Finland, Scan, J. Work Environ. Health 28
(2002) 16–20.
[29] M. Waked, J. Salame, G. Khayat, P. Salameh, Correlates of COPD and chronic
bronchitis in nonsmokers: data from a cross-sectional study, Int. J. Chronic Obstr.
Pulm. Dis. 7 (2012) 577–585.
[30] M.D. Eisner, J. Balmes, P.P. Katz, et al., Lifetime environmental tobacco smoke
exposure and the risk of chronic obstructive pulmonary disease, Environ. Health 4
(2005) 7, https://doi.org/10.1186/1476-069X-4-7.
[31] C. Protano, M. Manigrasso, P. Avino, M. Vitali, Second-hand smoke generated by
combustion and electronic smoking devices used in real scenarios: ultrafine particle
pollution and age-related dose assessment, Environ. Int. 107 (2017) 190–195.
[32] M. Oberg, M.S. Jaakkola, A. Woodward, A. Peruga, A. Pruess-Ustuen, Wordwide
burden of disease from exposure to second-hand smoke. a retrospective analysis of
data from 192 countries, Lancet 377 (2011) 139–146.
[33] R. Liu, Y. Jiang, Q. Li, S.K. Hammond, An assessment of health risks and mortality
from exposure to secondhand smoke in Chinese restaurants and bars, PLoS One 9
(2014) e84811.
[34] S. Ukawa, A. Tamakoshi, H. Yatsuya, K. Yamagishi, M. Ando, H. IsoJACC Study
Group, Passive smoking and chronic obstructive pulmonary disease mortality:
findings from the Japan collaborative cohort study, Int. J. Public Health 62 (2017)
489–494.
[35] R.M. Reed, M.T. Dransfield, M. Eberlein, et al., Gender differences in first and
secondhand smoke exposure, spirometric lung function and cardiometabolic health
in old order Amish: a novel population without female smoking, PLoS One 12 (3)
(2017) e0174354.
[36] M.D. Eisner, Y. Wang, T.J. Haight, J. Balmes, S.K. Hammond, I.B. Tager,
Secondhand smoke exposure, pulmonary function and cardiovascular mortality,
Ann. Epidemiol. 17 (2007) 364–373.
[37] P. Jousilahti, K. Patja, V. Salomaa, Environmental tobacco smoke and the risk of
cardiovascular disease, Scand. J. Work. Environ. Health 28 (suppl 2) (2002) 41–51.
[38] E.P. Rönmark, L. Ekerljung, J. Lötvall, K. Torén, E. Rönmark, B. Lundbäck, Large
scale questionnaire survey on respiratory health in Sweden: effects of late- and non-
response, Respir. Med. 103 (2009) 1807–1815.
[39] J.L. Pirkle, K.M. Flegal, J.T. Bernert, D.J. Brody, R.A. Etzel, K.R. Maurer, Exposure
of the US population to environmental tobacco smoke: the third national health and
nutrition examination survey, 1988 to 1991, J. Am. Med. Assoc. 275 (1996)
1233–1240.
[40] P. Vineis, I. Airoldi, P. Veglia, et al., Environmental tobacco smoke and risk of
respiratory cancer and chronic obstructive pulmonary disease in former smokers
and never smokers in the EPIC prospective study, BMJ 330 (2005) 277–280.
M.K. Pelkonen, et al. Respiratory Medicine 154 (2019) 34–39
39
